Spanish researchers found that individuals with sporadic Alzheimer's disease had inadequate STIM1 protein in medial frontal gyrus tissue, and by using CRISPR gene editing, they observed similar changes in neurons without the STIM1 protein and in brain tissues of people with Alzheimer's. The findings in the Journal of Molecular Medicine, which also showed that dihydropyridine-based pharmaceuticals stopped cell death caused by deficient STIM1, prompted researchers to consider STIM1 protein deficiency as a biomarker of sporadic Alzheimer's.
Study identifies biomarker of sporadic Alzheimer's disease
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.